New cancer drug TAK-243 enters human safety trials
NCT ID NCT06223542
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 16 times
Summary
This early-stage study tests the safety and best dose of TAK-243, a drug that targets a protein cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma who have tried other treatments will receive TAK-243. The goal is to find side effects and the right dose, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.